Nippon Shokubai to Increase Nucleic Acid Drug API Production Capacity Tenfold

Nippon Shokubai to Expand Nucleic Acid Drug API Manufacturing



Nippon Shokubai Co., Ltd., a leading chemical manufacturer headquartered in Osaka, Japan, has unveiled ambitious plans to significantly expand its manufacturing capacities for GMP-compliant nucleic acid drug active pharmaceutical ingredients (APIs). With the global nucleic acid drug market witnessing a surge in demand, the company aims to increase its production capacity tenfold in response to this growth.

Nucleic acid drugs, characterized by their chemically synthesized oligonucleotides, function by exerting therapeutic effects without being converted into proteins. As scientific advancements continue to progress, these drugs are expected to play a pivotal role in addressing challenging medical conditions, including rare diseases, neurological disorders, and various forms of cancer. Conventional treatments for these medical issues have often been limited.

Current projections indicate that the global market for nucleic acid drugs could exceed ¥1,400 billion by the year 2030. Furthermore, the Contract Development and Manufacturing Organization (CDMO) segment for nucleic acid drugs is anticipated to grow at an average annual rate of 14% from 2021 to 2030, eventually reaching a value of ¥200 billion. This upward trajectory highlights the increasing expectations from pharmaceutical companies both within Japan and internationally regarding the enhancement of Nippon Shokubai’s GMP-compliant manufacturing capabilities.

The planned expansion involves the installation of a large-scale production line, which will boast ten times the capacity of the existing facility, allowing the company to produce several kilograms per batch. Set to commence operations in 2027, this new facility will emerge as one of Japan's largest CDMOs, thereby enhancing the capability to manufacture APIs for prevalent diseases that require robust supply chains.

To ensure comprehensive fulfillment of global demands, Nippon Shokubai’s enhancement will involve a streamlined manufacturing system that accommodates various stages of drug development, ranging from non-clinical phases to large-scale commercial production.

Nippon Shokubai’s expertise in organic synthesis and dedication to quality control is central to their reputation. The company's facilities have been recognized as among the most advanced in Japan, having undergone audits and inspections by multiple pharmaceutical corporations, all of which have affirmed Nippon Shokubai's notable standing in the industry. In light of this expansion, the company remains committed to providing flexible contract manufacturing services tailored to the diverse needs of its clients and is dedicated to contributing to societal well-being by ensuring a stable supply of medium-sized molecule APIs essential for human health.

As the company looks towards the future, its mission is clear: to lead in the production of nucleic acid drugs, paving the way for novel therapeutic solutions and responding proactively to the increasing demands of a global health market.

By investing in its manufacturing capabilities, Nippon Shokubai not only aims to solidify its position as a key player in the pharmaceutical landscape but also to ensure that innovative treatments are accessible to patients worldwide.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.